PCNSL (ML)

ML-3
A CASE OF PRIMARY CENTRAL NERVOUS SYSTEM ANAPLASTIC LYMPHOMA KINASE POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA AT NEUROHYPOPHYSIS AND PINEAL GLAND. Shohei Kohno1, Ryo Omae1, Aiko Shinko1, Kazuya Takahashi1; 1Department of Neurosurgery, Juntendo University Hospital, Tokyo, Japan

The majority of primary central nervous system (CNS) lymphomas (PCNSL) are diffuse large B-cell lymphomas. Anaplastic large cell lymphoma (ALCL) is a type of T-cell tumor that is very rare in the PCNSL. ALCLs are divided into two entities: anaplastic lymphoma kinase (ALK)-positive and ALK-negative. We report a case of a 26-year-old woman who presented with a one month history of headache and nausea. Magnetic resonance imaging (MRI) of the brain revealed primary and pineal gland mass diagnosed as ALK-positive ALCL by endoscopic brain biopsy. She underwent chemotherapy following methotrexate (MTX) and cyclophosphamide + doxorubicin + vincristine + prednisolone (CHOP). The follow-up contrast-enhanced brain MRI showed no recurrent lesion after chemotherapy. In previous reports, most of the lesions were in cerebral hemisphere, dura mater and spinal cord. Many of these patients were given primary diagnoses of meningitis. To our knowledge, there is no case report of initial diagnosis of germinoma due to lesions in Neurohypophysis and pineal gland as in this case.

Key words: primary central nervous system lymphomas | anaplastic large cell lymphoma | anaplastic lymphoma kinase | Neurohypophysis and pineal gland

ML-4
A CASE OF PRIMARY CNS LYMPHOMA DIAGNOSED 5 YEARS AFTER STEREOTACTIC RADIOSURGERY. Yusuke Tabei1, Kihoru Nakazato1, Kenichi Oyama1, Masato Kawashima2, Akira Matsuou1, Ryutaro Nomura2; 1Department of Neurosurgery,International University of Health and Welfare,Mita Hospital 1Chigasaki cho hospital cyberknife center

Central nervous system primary malignant lymphoma (PCNSL) is rarely diagnosed as multiple metastatic brain tumors. Almost tumors recur early after receiving stereotactic radiosurgery (SRS). Regardless of the fact, the following case report displays PCNSL, diagnosed five years after the initial treatment with SRS as brain metastases of unknown primary origin. This extraordinary case suggests long-term follow-up regarding PCNCL. The case was a 35-year-old woman with a history of a total hysterectomy for cervical cancer. She developed left parietal brain MRI confirmed a 2 cm contrast-enhanced lesion in the right frontal lobe and three other lesions. SRS was performed as a diagnosis of multiple brain metastases for urgent symptom relief. No extra-cranial cancers were found. Unknown primary cancer was a probable diagnosis at that time. Two years after SRS, local growth of tumor of the right frontal primary motor area was discovered. Re-irradiation was performed. Cerebral edema, contrast enhancement, and left paralysis progressed following five months, taking an oral corticosteroid. Craniotomy and debulk. The pathological diagnosis was brain radiation necrosis due to no viable tumor cells. New lesions in the left temporal lobe and basal ganglia appeared three years after surgery. Awake craniotomy was performed for the left temporal lobe lesion. Histopathology showed diffuse growth of tumor cells with a high nuclear-cytoplasmatic ratio and irregular nuclear shape. Immunohistochemistry revealed positive CD10, CD20, CD45 (LCA), MUM1, and negative CD3, CD5. The Ki-67 labeling rate was as high as almost 100% to diagnose diffuse large B-cell lymphoma, PCNSL. Multidrug chemotherapy consisting of rituximab, high-dose methotrexate, procarbazine, and vincristine were performed. Complete remission was obtained without any serious adverse events. Considering the residual radiation necrosis, whole-brain irradiation was avoided. Moreover, consolidation therapy was performed only with high-dose cytarabine therapy.

Key words: primary CNS lymphoma | stereotactic radiosurgery | delayed diagnosis

ML-7
LIQUID BIOPSY FOR MYD88 MUTATION IN CEREBROSPINAL FLUID IN PATIENTS WITH SUSPECTED PRIMARY CNS LYMPHOMA Yamagishi FLUID IN PATIENTS WITH SUSPECTED PRIMARY CNS LYMPHOMA. Tomohide Nishikawa1, Yoshihi Shikawa1, Katsuhisa Ichimura1, Motoo Nagane1; 1Department of Neurosurgery, Kyorin University Graduate School of Medicine, Tokyo, Japan

Relapsing/refractory primary CNS lymphoma (r/r PCNSL) is a rare but fatal disease that is often highly resistant to treatment. In recent years, there has been a growing interest in liquid biopsy for the detection of circulating tumor DNA (ctDNA) to monitor disease progression and response to therapy in r/r PCNSL. In this study, we aimed to evaluate the feasibility and clinical utility of liquid biopsy for the detection of MYD88 mutation in cerebrospinal fluid (CSF) of patients with r/r PCNSL.

Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, etc. We are developing a CNSL diagnostic method based on the detection of MYD88 L265P mutation by digital PCR (dPCR) using CSF-DNA, and a high accuracy with a sensitivity of 92.9% and a specificity of 100% has been reported. Here, we report two cases with suspected brain stem CNSL, whose treatment strategy was determined by integrated clincor-laboratory information including neurologic presentations, imagological findings, and the result of liquid biopsy.

Result: Case 1. A 63-year-old woman visited our hospital with a complaint of right hemiplegia, which deteriorated in two months. MR images revealed a contrast-enhancing lesion in the left midbrain-ventral pons, suggesting CNSL. Biopsy was not considered because of its location, while dPCR using CSF-DNA showed a cluster of MYD88 mutation signals. Based on these work-ups, she was treated with high-dose methotrexate-based chemotherapy, resulting in a complete response with marked improvement of symptoms. Case 2. An 83-year-old man was referred for a history of diplopia and ataxia lasting for a month. MR images revealed an invasive lesion on his right midbrain-dorsal pons. Biopsy was declined due to the location, and liquid biopsy using CSF-DNA was performed to assist the diagnosis. In the first test, the CSF-DNA yield was too insufficient to determine the mutation signal by dPCR. The second dPCR using sufficient amount of CSF-DNA resulted in the Target/Total value of 0.049% which was lower than the threshold, suggesting the absence of MYD88 mutation. The patient underwent radiation therapy accordingly. Conclusions: CSF MYD88 mutation analysis by dPCR may have clinical utility and requires sufficient amount of CSF-DNA for exclusion of noise signals.

Key words: liquid biopsy | MYD88 | digital PCR

ML-10
TIRABRUTINIB, A SECOND-GENERATION BTK INHIBITOR IN RELAPSED AND REFRACTORY PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTE STUDY. Kazuhiko Mishima1, Shirahata Mitsuki1, Junichi Adachi1, Tomonari Suzuki1, Eita Uchida1, Ryo Nishikawa1; 2Department of Neuro-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan

Background: Treatment intervention for central nervous system lymphoma (CNSL) is rarely diagnosed as multiple metastatic brain tumors. Almost tumors recur early after receiving stereotactic radiosurgery (SRS). Regardless of the fact, the following case report displays PCNSL, diagnosed five years after the initial treatment with SRS as brain metastases of unknown primary origin. This extraordinary case suggests long-term follow-up regarding PCNCL. The case was a 35-year-old woman with a history of a total hysterectomy for cervical cancer. She developed left parietal brain MRI confirmed a 2 cm contrast-enhanced lesion in the right frontal lobe and three other lesions. SRS was performed as a diagnosis of multiple brain metastases for urgent symptom relief. No extracranial cancers were found. Unknown primary cancer was a probable diagnosis at that time. Two years after SRS, local growth of tumor of the right frontal primary motor area was discovered. Re-irradiation was performed. Cerebral edema, contrast enhancement, and left paralysis progressed following five months, taking an oral corticosteroid. Craniotomy and debulk. The pathological diagnosis was brain radiation necrosis due to no viable tumor cells. New lesions in the left temporal lobe and basal ganglia appeared three years after surgery. Awake craniotomy was performed for the left temporal lobe lesion. Histopathology showed diffuse growth of tumor cells with a high nuclear-cytoplasmic ratio and irregular nuclear shape. Immunohistochemistry revealed positive CD10, CD20, CD45 (LCA), MUM1, and negative CD3, CD5. The Ki-67 labeling rate was as high as almost 100% to diagnose diffuse large B-cell lymphoma, PCNSL. Multidrug chemotherapy consisting of rituximab, high-dose methotrexate, procarbazine, and vincristine were performed. Complete remission was obtained without any serious adverse events. Considering the residual radiation necrosis, whole-brain irradiation was avoided. Moreover, consolidation therapy was performed only with high-dose cytarabine therapy.

Key words: primary CNS lymphoma | Brutton's tyrosine kinase inhibitor | Tibrabrutinib

ML-11
TIRABRUTINIB TREATMENT FOR RECURRENT OR REFRACTORY PCNSL Fumiharu Ohka1, Jyunya Yamaguchi1, Kazuya Motomura2, Kousuke Aoki1, Tomohide Nishikawa1, Yui Kibi1, Shintaro Yamazaki1, Atsunori Nishimine1, Ryuta Saito1; 1Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

Since 2020, tirabrutinib which is a Brutton's tyrosine kinase (BTK) inhibitor has been available for recurrent or refractory PCNSL cases. The number of studies reporting efficiency and adverse effect of tirabrutinib
Abstracts

NEURO-ONCOLOGY ADVANCES • December 2021

ML-12
CLINICAL IMPACT AND MANAGEMENT OF SKIN-RELATED DISORDERS DURING TREATMENT OF RELAPSED PCNSL BY TIRABRUTINIB

Nobuyoshi Sakui1, Keiichi Kobayashi1, Kunika Saito1, Ryo Onoda1, Yosuke Seiya1, Saki Suzuki1, Yuki Yamagishi2, Hirofumi Nakatomi3, Yoshiaki Shiokawa1, Motoo Naganee1;1Department of Neurosurgery, Kyorin university faculty of medicine, Tokyo, Japan 2Division of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan 3Department of Neurosurgery, Kyorin University Graduate School of Medicine, Tokyo, Japan

BACKGROUND: Tirabrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD) are the most prevalent adverse event in tirabrutinib, which accounted for 54.5% in a phase II trial. While the use of tirabrutinib is increasingly considered in clinical practice, the prevalence and clinical impact of tirabrutinib-related SRDs in real-world practice remains unclear. METHODS: Relapsed PCNSL patients treated with tirabrutinib at the author’s institution were identified, and divided into those with SRDs (SRD group), and without SRDs (non-SRD group). Response rate and progression-free survival (PFS) were retrospectively analyzed and compared between the two groups. RESULTS: Eleven patients were identified (median age: 73 [range: 50–83], median KPS: 70 [range: 40–90]), which included six (54.5%) from the SRD group and five (45.5%) from the non-SRD group. Response rate was 100% in the SRD group and 60% in the non-SRD group. Median PFS was 2.8 months in the SRD group and 36.3 months in the non-SRD group, which yielded no significant difference (p=0.446). While antihistamine prophylaxis using fexofenadine was performed in seven patients, among them SRDs were observed in three (27.3%). SRDs lead to tirabrutinib interruption (for ten days or more) in two patients (18.2%), dose reduction in three (27.3%), and discontinuation in two patients (18.2%). Four patients in whom tirabrutinib was interrupted or discontinued due to SRDs had shorter PFS, compared with the two patients from the SRD group which yielded no significant difference (p=0.049). CONCLUSIONS: SRDs substantially lead to tirabrutinib interruption or discontinuation, which could result in early PD. Since fexofenadine prophylaxis seems ineffective for preventing SRDs, other antihistamines should be established. Establishment of the optimal management of tirabrutinib-related SRDs is warranted.

Key words: Tirabrutinib | PCNSL | Skin rash

ML-16
FIRST CLINICAL EXPERIENCE OF ADMINISTRATION OF TIRABRUTINIB FOR THE PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Sho Onodera1, Jiro Akimoto1;1Department of Neurosurgery, Kosei Chuo General Hospital

Tirabrutinib (TIR), a Burton’s tyrosine kinase inhibitor, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refractory PCNSL using TIR.

Three patients, 48, 78 and 88 years-old, diagnosed with PCNSL by histologically verification were firstly treated with high dose Methotrexate based chemotherapy (HD-MTX) and/or radiotherapy, however these cases were refractory for these standard treatments; demonstrated early cerebrospinal fluid dissemination or accompanied with severe adverse event. The authors decided to administrate TIR to these patients with a full informed consent. TIR demonstrated dramatic reduction of the volume of tumor on MRI within one month after administration of TIR, and improved the patient’s performance status. However, one case demonstrated liver dysfunction and multiple brain abscess due to aspergillus infection, and one case demonstrated early progression of the tumor 49 days after starting TIR.

Administration of TIR for the patients with newly diagnosed refractory PCNSL demonstrated a rapid and dramatic clinical response, and presented with several clinical implications for this complicated condition.

Key words: Tirabrutinib | refractory primary central nervous system lymphoma | adverse event

ML-17
CLINICAL USEFULNESS OF TIRABRUTINIB IN RECURRENT PCNSL: SINGLE INSTITUTE EXPERIENCE

Jin Matsura1, Jun-Ichiro Kuroda1, Tatsuya Takezaki1, Naoki Shinjojima1, Akitake Mukasa1;1Department of Neurosurgery, University of Kamamoto, Kamamoto, Japan

Background: Primary central nervous system lymphoma (PCNSL) is a lymphoma whose primary lesion is localized in the brain and spinal cord. Treatment is a combination of high-dose methotrexate-based chemotheraphy and whole-brain irradiation, often leading to recurrence. Pathologically, non-GCB type diffuse large B-cell lymphoma (DLBCL) predominates. In DLBCL, constitutive activation of B cell receptor signal (BCR) is the tumor mechanism of tumor development and growth. Tirabrutinib is an inhibitor of Burton’s tyrosine kinase (BTK) located downstream of BCR. In a phase I / II study, an overall response rate was 64%. Currently, Tirabrutinib is a drug that has just been approved, and there are few reports of its use in clinical practice. We report on our experience with Tirabrutinib with a review of the literature. Methods: We retrospectively examined the clinical course of 11 recurrent PCNSL patients treated with Tirabrutinib at our institution. Results: The average age of the subjects was 68.7 years, and 7 cases were male. Tirabrutinib 480 mg was administered in all cases. The response rate was 60% (6/10 cases). The median progression-free survival was 4.3 months. The adverse events were Grade 3 neutropenia in 1 patient and Grade 2 skin disorder in 4 patients. Treatment was discontinued in 5 of the 11 patients due to progression of the disease. In our experience, Tirabrutinib was reduced to 320 mg in 1 patient and discontinued in 1 patient. Treatment was discontinued at the request of the patient in 1 case, and four patients are still receiving the drug.

Key words: Primary central nervous system lymphoma | Methotrexate | Tocilizumab

ML-13
PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA IN A PATIENT WITH RHEUMATOID ARTHRITIS RECEIVING TOCILIZUMAB

Masasuke Ohno1, Sanychiro Kuramitsu2, Shoyo Ito2, Masayuki Kimata1, Takumi Asa1, Norihiro Sakui1, Yasuaki Kasai1, Tatsuo Takahashi1;1The Department of Neurosurgery, Aichi Cancer Center Hospital, Nagoya, Japan 2Department of Neurosurgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Background: Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, the occurrence of primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rare. In recent years, there has been concern that biological disease-modifying anti-rheumatic drugs (DMRADs), which are widely administered to patients with RA, may increase the risk of developing cancer. We report the first case of PCNSL in a patient with RA who was treated with the biological DMRADs, tocilizumab. Case description: A 70-year-old man, who was diagnosed with RA in 2010 was treated with low-dose methotrexate from 2010 to 2015. He was started on tocilizumab in 2012. In 2018, he suffered from gait disturbance and was diagnosed with lumbar spinal stenosis. He underwent L2/3 posterior fusion surgery, but his paraplegia gradually deteriorated. He was referred to our department for Gd contrast-enhanced lesions in the basal ganglia and brain stem. A stereotactic brain biopsy was performed and DLBCL was diagnosed, and finally PCNSL was diagnosed because of no neoplastic lesions in other organs. He was treated with 3 courses of 3.5g/m2 with rituximab and has been in remission for 23 months. He has maintained an independent life with residual paraplegia, but his ADLs gradually worsened. He was restarted on tocilizumab with a diagnosis of worsening RA. Conclusion: Low-dose methotrexate and biological DMRADs including tocilizumab, have been concerned to increase the risk of cancer in patients with RA, but there is no solid evidence. Since it has been a short time since the use of biological DMRADs, further accumulation of cases and careful follow-up are necessary.

Key words: Primary central nervous system lymphoma | Methotrexate | Tocilizumab

treatment for recurrent or refractory PCNSL has been limited yet. In this study, we investigated clinical course of eight recurrent or refractory PCNSL cases treated with tirabrutinib in our institute.

Eight PCNSL cases treated with tirabrutinib included four recurrent cases and four refractory cases. Five cases obtained CR or PR after 26.8 days administration of tirabrutinib and other two cases also exhibited obvious improvement of clinical symptoms after 23.3 days administration of tirabrutinib. Two cases exhibited intracranial lesions, two cases revealed improvement of visual dysfunction and the other case obtained SD status of intracranial lesion. The most frequently found adverse effect was the skin rash. CTCAE grade 2 (n=2) or 3 (n=2) rash was found after mean 1.6 days of tirabrutinib administration, respectively. Two cases with grade 3 rash could start taking the low-dose tirabrutinib after improvement of rash. Although one case experienced shingles, no other case experienced serious adverse effects.

Although adverse effect of rash was frequently found, we could obtain high response rate of tirabrutinib treatment for recurrent or refractory PCNSL cases. We need to establish quantitative assessment method for analysis of treatment response of tirabrutinib for intracranial lesions.

Key words: Tirabrutinib | PCNSL | Skin rash